Medicilon: The company has fulfilled its contractual obligations, and Hongxu Biotech has yet to pay the remaining contract amount of 557,600 yuan

On September 23rd, Medicilon issued a statement stating that Hongxu Biotechnology recently published an article titled "Statement by Hongxu Biotechnology on Filing a Lawsuit Against Medicilon in Accordance with the Law" on its WeChat public account "Hongxu Biotechnology." The content described by Hongxu Biotechnology in the article is seriously inconsistent with the objective facts. As it involves the signing of contracts, details of performance, and the determination of breach of contract liability, these are all core disputes of the lawsuit, which await clarification by the people's court and subsequent publication. Medicilon stated in the announcement that the company has fully and appropriately fulfilled its contractual obligations. As of the date of this announcement, Hongxu Biotechnology has not paid the remaining contract amount of RMB 557,600 to the company, and the company reserves the right to pursue recovery through all legal means